Cancel the denosumab holiday

5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial

(2015) Nina D. Wagner-Johnston et al.   CANCER

Denosumab: A novel antiresorptive drug for osteoporosis

(2015) E. SURESH et al.   CLEVELAND CLINIC JOURNAL OF MEDICINE

Persistence with denosumab therapy among osteoporotic women in the Canadian patient-support program

(2015) Alexandra Papaioannou et al.   CURRENT MEDICAL RESEARCH AND OPINION

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial

(2015) Michael Gnant et al.   LANCET

Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study

(2015) P. Hadji et al.   OSTEOPOROSIS INTERNATIONAL

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

(2015) S. Papapoulos et al.   OSTEOPOROSIS INTERNATIONAL

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years

(2015) S. Ferrari et al.   OSTEOPOROSIS INTERNATIONAL

Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial

(2015) S. L. Greenspan et al.   OSTEOPOROSIS INTERNATIONAL

Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis

(2015) L. Karlsson et al.   OSTEOPOROSIS INTERNATIONAL

Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases

(2014) M O'Halloran et al.   AUSTRALIAN DENTAL JOURNAL

A Meta-Analysis of Reference Markers of Bone Turnover for Prediction of Fracture

(2014) Helena Johansson et al.   CALCIFIED TISSUE INTERNATIONAL

Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study

(2014) S. L. Silverman et al.   OSTEOPOROSIS INTERNATIONAL

Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women’s Health Initiative Randomized Trials

(2013) JoAnn E. Manson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Understanding and Communicating the Benefits and Risks of Denosumab, Raloxifene, and Teriparatide for the Treatment of Osteoporosis

(2013) E. Michael Lewiecki et al.   JOURNAL OF CLINICAL DENSITOMETRY

Treat-to-target for Osteoporosis: Is Now the Time?

(2013) E. Michael Lewiecki et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial

(2013) Joy N Tsai et al.   LANCET

Five years of anti-resorptive activity after a single dose of zoledronate — Results from a randomized double-blind placebo-controlled trial

(2012) Andrew Grey et al.   BONE

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Five years of continued therapy in a phase 2 study

(2012) Bente Langdahl et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial

(2012) Jacques P Brown et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The relationship of denosumab pharmacology and osteonecrosis of the jaws

(2012) John Malan et al.   Oral Surgery Oral Medicine Oral Pathology Oral Radiology

Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation

(2011) Philipp Diehl et al.   Clinical Research in Cardiology

Health Outcomes After Stopping Conjugated Equine Estrogens Among Postmenopausal Women With Prior Hysterectomy

(2011) Andrea Z. LaCroix   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

(2011) Dennis M Black et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

(2011) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Hip fracture in postmenopausal women after cessation of hormone therapy

(2011) Roksana Karim et al.   MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY

Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women

(2011) N. Freemantle et al.   OSTEOPOROSIS INTERNATIONAL

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect

(2010) John A Eisman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

(2009) Matthew R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass

(2009) Michael McClung et al.   OBSTETRICS AND GYNECOLOGY

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial

(2008) Paul D. Miller et al.   BONE

Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin

(2008) Gerardo Heiss   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION